Horizon Pharma plc Files Patent Infringement Lawsuit Against Watson Laboratories, Inc. for Filing an ANDA Against PENNSAID(R) 2%
Marketwired - Wed Dec 24, 12:00PM CST
Horizon Pharma plc (NASDAQ: HZNP), a specialty biopharmaceutical company with a portfolio of products in arthritis, inflammation and orphan diseases, announced today that the Company has filed a patent infringement lawsuit in the United States District Court for the District of New Jersey against Watson Laboratories, Inc. ("WLF"
HZNP: 12.38 (+0.13)
5 Best Performing Stocks of the Nasdaq in 2014 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 24, 9:58AM CST
The tech-laden Nasdaq Composite index enjoyed a bull run this year banking on broad based gains among Internet and bio-tech stocks, better-than expected GDP numbers and Fed's assurance about the economy.
CMRX: 36.80 (+0.70), SWKS: 74.32 (+0.92), IBM: 161.82 (-0.42), CHL: 59.15 (-0.02), HZNP: 12.38 (+0.13), TKMR: 13.97 (+0.14), GOOGL: 536.93 (-1.84), MSFT: 48.14 (-0.31), AAPL: 112.01 (-0.53), PLNR: 7.04 (-0.15), AVGO: 100.72 (-0.06), RFMD: 16.59 (+0.29)
Cheap Stocks for 2015: The Best Buys in Healthcare
Todd Campbell, The Motley Fool - Motley Fool - Wed Dec 10, 9:33AM CST
Source: Cigna. Healthcare has been one of the best-performing sectors in 2014, and investors are right to question whether stocks in the industry will continue their winning ways in 2015. While increasing share prices have made many healthcare...
CI: 104.23 (-0.08), GILD: 91.29 (+1.84), CYH: 55.36 (+0.37), HZNP: 12.38 (+0.13), TEVA: 57.09 (+0.33)
Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance
PR Newswire - Wed Nov 26, 7:35AM CST
Investor-Edge has initiated coverage on the following equities: VIVUS Inc. (NASDAQ:VVUS), Horizon Pharma PLC (NASDAQ: HZNP), Endocyte Inc. (NASDAQ: ECYT), Johnson and Johnson (NYSE: JNJ), and Theravance Inc. (NASDAQ: THRX). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Tuesday, November 25, 2014, the NASDAQ Composite ended at 4,758.25, up 0.07%, the Dow Jones Industrial Average edged 0.02% lower, to finish the day at 17,814.94, and the S&P 500 closed at 2,067.03, down 0.12%. During the session, five out of ten sectors ended in positive. The S&P 500 Health Care Sector Index ended the day at 793.40, up 0.07%, with the index also advancing 8.30% in the previous three months. Register for your complimentary reports on these five stocks at:
JNJ: 104.59 (+0.31), ECYT: 6.33 (+0.24), HZNP: 12.38 (+0.13), VVUS: 2.99 (-0.02), THRX: 14.55 (+0.22)
InsiderInsights.com Daily Round Up 11/20/14: NES, OPK, OKS, PAH
InsiderInsights - at Seeking Alpha - Mon Nov 24, 2:04PM CST
NES: 4.96 (-0.44), RAX: 48.24 (+0.45), JAH: 47.91 (+0.10), LNG: 71.64 (-0.12), MRD: 18.64 (-0.53), PAH: 23.00 (+0.01), AON: 96.52 (-0.15), SGM: 12.35 (+0.05), CLI: 19.06 (-0.03), CNCE: 11.76 (+0.11), VSAR: 22.25 (-0.11), OPK: 9.63 (+0.21), HZNP: 12.38 (+0.13), CATY: 25.60 (+0.09), IMH: 6.25 (-0.06), OKS: 41.05 (-0.04), GRPN: 7.89 (-0.14), SFXE: 4.42 (+0.04), SCHW: 30.67 (+0.01)
Horizon Pharma plc to Present at the 26th Annual Piper Jaffray Healthcare Conference
Marketwired - Mon Nov 24, 7:01AM CST
Horizon Pharma plc (NASDAQ: HZNP), a specialty biopharmaceutical company with a portfolio of products in arthritis, inflammation and orphan diseases, today announced that Robert F. Carey, executive vice president and chief business officer, and Paul W. Hoelscher, executive vice president and chief financial officer, will present at the 26th Annual Piper Jaffray Healthcare Conference on Wednesday, December 3, 2014 at 1:30 p.m. Eastern Time in New York, NY.
HZNP: 12.38 (+0.13)
Horizon Pharma plc Announces Presentation of Data Showing Unmet Need in Rheumatoid Arthritis and the Positive Effect of RAYOS(R) (Prednisone) Delayed-Release Tablets in Reducing Joint Stiffness of RA Throughout the Day
Marketwired - Wed Nov 19, 3:44PM CST
Horizon Pharma plc (NASDAQ: HZNP) today announced the presentation of data from five abstracts that review unmet needs in rheumatoid arthritis ("RA"
HZNP: 12.38 (+0.13)
InsiderInsights.com Daily Round Up 11/17/14: SFM, INTX, GNRC, GSAT
InsiderInsights - at Seeking Alpha - Tue Nov 18, 5:55AM CST
HCOM: 27.34 (+0.27), IPHI: 15.51 (-0.01), JBHT: 84.91 (-0.02), COV: 103.35 (+0.57), OPHT: 44.93 (+1.06), COP: 70.13 (-0.92), SFM: 32.70 (+0.02), GOOG: 528.77 (-1.82), GSAT: 2.97 (+0.03), STAY: 19.60 (-0.31), ZOES: 29.59 (+1.08), INTX: 3.83 (-0.03), GNRC: 47.26 (-0.24), HZNP: 12.38 (+0.13), TRUE: 23.50 (+0.31)
Horizon Pharma discloses pricing of secondary offering of 11.66m ordinary shares
M2 - Mon Nov 17, 6:04AM CST
Biopharmaceutical company Horizon Pharma (NasdaqGS:HZNP) said on Friday that it has priced a secondary public offering of 11,660,445 of its ordinary shares.
HZNP: 12.38 (+0.13)
Horizon Pharma: A Strong Buy Following The Q3 Report
ONeil Trader - at Seeking Alpha - Sat Nov 15, 8:39AM CST
HZNP: 12.38 (+0.13)
Horizon Pharma plc Announces Pricing of Secondary Offering of Ordinary Shares by Selling Shareholders
Marketwired - Fri Nov 14, 7:03AM CST
Horizon Pharma plc (NASDAQ: HZNP), a specialty biopharmaceutical company with a portfolio of products in arthritis, inflammation and orphan diseases, today announced the pricing of a previously announced underwritten secondary offering of 11,660,445 of its ordinary shares held by certain of its existing shareholders, offered at a price to the public of $12.05 per share. Horizon Pharma plc is not issuing new ordinary shares and will not receive any proceeds from the sale of ordinary shares by the selling shareholders in the offering. The offering is expected to close on or about November 19, 2014, subject to customary closing conditions.
HZNP: 12.38 (+0.13), MS: 38.81 (-0.14)
Strong Earnings And Low Valuation To Catalyze Horizon Pharma
David Zanoni - at Seeking Alpha - Thu Nov 13, 8:30AM CST
HZNP: 12.38 (+0.13)
Horizon Pharma plc Announces Proposed Secondary Offering of Ordinary Shares by Selling Shareholders
Marketwired - Thu Nov 13, 6:03AM CST
Horizon Pharma plc (NASDAQ: HZNP), a specialty biopharmaceutical company with a portfolio of products in arthritis, inflammation and orphan diseases, today announced a proposed underwritten secondary offering of 11,660,445 of its ordinary shares held by certain of its existing shareholders. Horizon Pharma plc is not issuing new ordinary shares and will not receive any proceeds from the sale of ordinary shares by the selling shareholders in the offering.
HZNP: 12.38 (+0.13), MS: 38.81 (-0.14)
Horizon Pharma plc Announces Clinical Data on RAYOS(R) (Prednisone) Delayed-Release Tablets and VIMOVO(R) (Naproxen/Esomeprazole Magnesium) to Be Presented at the American College of Rheumatology Annual Meeting
Marketwired - Wed Nov 12, 3:09PM CST
Horizon Pharma plc (NASDAQ: HZNP) today announced that four abstracts related to RAYOS (prednisone) delayed-release tablets and one abstract on VIMOVO (naproxen/esomeprazole magnesium) will be presented during the American College of Rheumatology (ACR) and Association of Rheumatology Health Professionals (ARHP) Annual Scientific Meeting taking place November 15 to 19, 2014 in Boston, MA.
HZNP: 12.38 (+0.13)
Horizon Pharma plc Announces Favorable Markman Ruling in RAYOS(R) (prednisone) Delayed-Release Tablets Patent Infringement Litigation
Marketwired - Wed Nov 12, 7:05AM CST
Horizon Pharma plc (NASDAQ: HZNP), a specialty biopharmaceutical company with a portfolio of products in arthritis, inflammation and orphan diseases, today announced that a favorable Markman ruling has been issued by Judge Joseph E. Irenas of the United States District Court for the District of New Jersey in the patent infringement lawsuit filed by Horizon against Watson Laboratories, Inc. for an Abbreviated New Drug Application ("ANDA"
HZNP: 12.38 (+0.13)
Horizon Pharma plc to Present at the Stifel 2014 Healthcare Conference
Marketwired - Tue Nov 11, 3:05PM CST
Horizon Pharma plc (NASDAQ: HZNP), a specialty biopharmaceutical company with a portfolio of products in arthritis, inflammation and orphan diseases, today announced that Robert F. Carey, executive vice president and chief business officer, will present at the Stifel 2014 Healthcare Conference on Tuesday, November 18, 2014 at 4:45 p.m. Eastern Time in New York, NY. Mr. Carey will provide an overview of the Company and its corporate activities.
HZNP: 12.38 (+0.13)
Horizon Pharma's (HZNP) CEO Timothy Walbert on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Nov 06, 12:20PM CST
HZNP: 12.38 (+0.13)
Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 8:14AM CST
ACAS: 14.95 (+0.12), WWWW: 19.23 (-0.03), PHMD: 1.46 (-0.03), RVLT: 1.28 (-0.02), SNMX: 5.95 (+0.34), PBR: 7.60 (-0.11), QCOM: 74.66 (+0.06), GNRC: 47.26 (-0.24), HZNP: 12.38 (+0.13), PESI: 4.38 (unch), WAC: 16.73 (-0.15), TRUE: 23.50 (+0.31), KATE: 29.83 (+0.44), DRYS: 1.20 (-0.04), Z: 104.60 (-0.16), WFM: 48.67 (-0.40), SWIR: 47.29 (+0.13), COT: 6.90 (-0.03), CSOD: 36.66 (-0.14), MCP: 0.72 (+0.01), GNW: 8.40 (+0.01), CECO: 6.72 (+0.09), GERN: 3.06 (+0.05), NDLS: 25.88 (+0.20), MEET: 1.51 (unch), AEZS: 0.59 (-0.02), DATA: 88.76 (+0.04), PLNR: 7.04 (-0.15), SZYM: 2.70 (+0.04)
Horizon Pharma elects John J. Kody as EVP
M2 - Thu Nov 06, 7:22AM CST
Biopharmaceutical company Horizon Pharma (NasdaqGS:HZNP) said on Thursday that its board has named John J. Kody as its executive vice president and chief commercial officer, as well as to its executive committee.
HZNP: 12.38 (+0.13), DHR: 86.79 (-0.27)
Horizon Pharma (HZNP) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Thu Nov 06, 6:55AM CST
HZNP: 12.38 (+0.13)